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Summary Hormonally insensitive prostate cancer is a relatively slow-growing, but usuallyfatal, disease with no long-term treatment options.
Transformation of normal prostate cells to a malignant phenotype often involves corruption of the apoptotic machineries. Bcl-2 protein is one
of the key inhibitors of apoptosis and is often unregulated in advanced prostate cancer. The prostate cancer cell line DU-145 was used as a
model of a hormonally insensitive, advanced prostate cancer. Cell growth in liquid culture was significantly inhibited by antisense Bcl-2
oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on
combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Interestingly, growth inhibition occurred in the
absence of apoptosis as measured using two assay techniques. We hypothesize that in these recalcitrant cells the apoptotic pathway is
compromised at several levels, and Bcl-2 may play another role in promoting cell growth. The use of Bcl-2 antisense oligonucleotides plus
2-HPR may provide a novel approach to therapy of hormone-resistant prostate cancer.
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Prostate cancer has become the most frequently diagnosed non-
skin cancer among American men and the second leading cause of
cancer mortality in this group, with similar mortality rates in many
western European countries (Parker et al, 1997). Although the
rapid rise in the incidence ofprostate cancer may be, in part, due to
the increasing use ofthe prostate-specific antigen (PSA) blood test
by physicians (Jacobsen etal, 1995), the underlying increase in this
disease is probably real. Despite the increase in the incidence ofthe
disease and its large-scale effects, no successful long-term thera-
pies exist once the cancer progresses beyond the prostate capsule.
Advanced disease may be treated with hormonal ablation
therapy that targets the androgen dependence ofthe prostate gland.
Blockade of androgen stimulation is thought to lead to apoptosis
ofprostate epithelial cells and often leads to a reduction in tumour
volume and a partial orfull remission. In the majority ofremission
cases, the cancer will re-emerge in a few years as a poorly differ-
entiated androgen-independent tumour. These androgen-insensi-
tive prostate cancer cells do not undergo apoptosis and resist all
therapies. Thus more effective alternatives are needed to combat
the hormonally independent stage of the disease. Modifiers of
growth targeted to transformed cells should be able to either retard
cell growth (Novichenko et al, 1995), promote cell death (Welsh,
1994; Danesi et al, 1995; Li CJ et al, 1995; Planchon et al, 1995)
or induce cell differentiation to a quiescent, non-dividing stage
(Paquette and Koeffler, 1992; Samid et al, 1993; Liu et al, 1994;
Hsieh et al, 1995a).
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One such approach is the use of antisense oligonucleotides to
inhibit transcription of specific genes critical to cell viability and
propagation. Binding of oligonucleotides to target sequences of
mRNA forms a duplex that permits metabolic degradation and/or
inhibition of message translation. This method would inhibit the
up-regulation of growth-promoting genes required for enhanced,
uncontrolled proliferation ofmalignant cells.
The target gene in prostate cancer that is particularly appealing
for this approach is the proto-onocogene Bcl-2. The product ofthis
gene was originally characterized in follicular lymphomas, where
a t(14:18) translocation up-regulated expression under transcrip-
tional control of the heavy-chain immunoglobulin enhancer.
Overexpression ofBcl-2 protein extends the viability ofterminally
differentiated cells, possibly by inhibiting the normal process and
timing ofapoptosis (Zhai et al, 1996).
Deregulated overexpression of Bcl-2 has also been observed in
other malignant tissues, for example breast (Barbareschi et al,
1996), lung (Higashiyma et al, 1996) and prostate cancer. In
prostate cancer, increased expression has been correlated with
poor prognosis (Bauer et al, 1996) and the emergence of the
hormonally independent, apoptosis-resistant tumours (Apakama et
al, 1996; Krajewska et al, 1996; McConkey et al, 1996). Moreover,
stable transfection of LNCaP prostate cancer cells with Bcl-2
increased their in vivo tumorigenic potential and resistance to
apoptosis (Raffo et al, 1995) and expression of Bcl-2 protein
increased in LNCaP cells that had metastasized in nude mice
(McConkey et al, 1996).
Anotherapproach in thecontrol ofcell growth involves the use of
the physiologically active metabolites of vitamins A, namely all-
trans retinoic acid (ATRA) and its isomer 9-cis retinoic acid
(9cRA). These compounds mediate genomic effects by binding to
specific nuclear hormone receptors that function as ligand-induced
transcription factors. ATRA and 9cRA bind to the retinoic acid
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receptor (RAR), and 9cRA also binds to the retinoid X receptor
(RXR); each receptor has three subtypes: alpha, beta and gamma
(Pemrick et al, 1994). Many oftheir genomic effects are associated
with either inhibition of proliferation, induction of apoptosis or
differentiation as demonstrated in a variety of cancer cells derived
from several tissues (Peck and Bollag, 1991; Lotan, 1994; Trump,
1994; Niles, 1995; Saunders et al, 1995). We (Campbell et al, 1997;
de Vos et al, 1997) andothers (Pollard etal, 1991; Pienta etal, 1993;
Dahiya et al, 1994a and b; Blutt et al, 1997) have demonstrated that
retinoids may inhibit growth ofcertain prostate cancer cells lines at
relatively high dose. Retinoids have been used for the treatment of
acute myeloid leukaemia with remarkable clinical success, although
relapse may occur as resistant clones arise (Huang et al, 1988;
Chomienne et al, 1996; Kantarjian et al, 1996). The potential may
therefore exist to improve the clinical potential of differentiation
therapy by combining altemative strategies, involving lower, poten-
tiating doses of retinoids combined with other growth-inhibitory
strategies, such as antisense oligonucleotides.
We, therefore, investigated whether growth inhibition and apo-
ptosis could be induced in DU-145, a hormonally independent,
metastasis-derived prostate cancer cell line, by exposure to a
phosphorothioated antisense oligonucleotides targeted against
Bcl-2 mRNA alone or in combination with both naturally occur-
ring and synthetic retinoids.
MATERIALS AND METHODS
Cells
The DU-145 prostate cancer cell line established from a brain
metastasis was obtained from ATCC and maintained according to
their recommendations in Dulbecco's modified Eagle medium
(DMEM) containing 10% fetal calf serum.
Phosphorothioate oligonucleotide to BcI-2
The phosphorothioate oligonucleotide sequences were antisense,
5'-tct ccc agc gtg cgc cat-3' (AS), and sense control, 5'-tac cgc gtg
cga ccc tct-3' (S), which were generously supplied by Genta (San
Diego, CA, USA). These were dissolved in 10 mM Tris/EDTA
buffer (pH 7.5) as a stock solution stored at -20°C and diluted for
experimental purposes in phosphate-buffered saline (PBS) pH 7.5.
Cell growth assays
Measurement of oligonucleotide potency was determined using
dose-response studies in liquid culture. DU-145 prostate cancer
cells from 80% confluent cultures (3 x 105 cells) were plated on
10-cm tissue culture plates. After 4 days' exposure to either sense
or antisense oligonucleotides or vehicle alone (control), both
adherent and floating viable cells were counted after staining with
trypan blue. Separately, we undertook dose-response experiments
in the same assay system, with the retinoids all-trans-retinoic acid
(ATRA), 9-cis-retinoic acid (9cRA) and N-(2-hydroxyphenyl)all-
trans-retinamide (2-HPR). To enhance inhibition by theBcl-2 anti-
sense sequences, we examined their effects combined with the
various retinoids at 0.1 gM. All experiments were performed at
least three times in duplicate dishes per experimental point.
Percentage cell growth was calculated by comparing cell counts
from test dishes exposed to either sense or antisense oligo-
nucleotides with control dishes with no added oligonucleotides.
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Figure 1 Dose-response effects of sense (A) and antisense (U) Bcl-2
oligonucleotides on DU-145 prostate cancer cell number in liquid culture.
Cells were exposed for 4 days after which time they were counted. Results
are expressed as a mean percentage (± s.e.m.) of control with no
oligonucleotide. Each point represents the mean of at least three experiments
with duplicate dishes
Detection of apoptosis
Cells (3 x 105 cells) were plated into 10-cm dishes in the presence
of either S or AS oligonucleotides (2gM). Additionally, the AS
oligonucleotides were supplemented with 2-HPR (0.1 gM). The
expression ofphosphotidylserine on the cell surface was examined
after 18 and 36 h ofculture by using Annexin V FITC-conjugated
antibody (R&D Systems, Minneapolis, MN, USA) and subsequent
FACS analysis according to the manufacturer's recommendations.
Forthepositive control, thecells were treated forthe same duration
with the topoisomerase 1I-directed drug etoposide (50jg ml-1).
DNA fragmentation after culture for 96 h was measured as
described previously (Li X and Daryzynkiewicz, 1995), using the
same conditions as those used for Annexin V measurement of
apoptosis. Briefly, total cells, both suspended and adherent to the
plastic dishes, were harvested and fixed in 1% methanol-free
formaldehyde for 15 min and washed with PBS. Aftercell concen-
tration was corrected to 1 x 106 cells ml-', cells were fixed in 5 ml
of 70% ethanol. Single- and double-stranded DNA breaks were
labelled with bromodeoxyuridine triphosphate (BrD-UTP) for
40 min at 370C with terminal transferase (Boehringer Mannheim,
Mannheim, Germany). The cells were permeabilized with a 0.3%
Triton-X 100 in 0.5% bovine serum albumin (BSA)/PBS. Cells
that had DNA breaks were tagged by BrDUTP incorporation and
identified with a FITC-conjugated anti-BrDU antibody. Cells were
stained with propidium iodide (PI) for 30 min, and green fluores-
cence was measured by FACS analysis at 510-550 nm. As a
positive control, cells were treated with etoposide (50 jig ml-') for
4 days.
Examination of Bcl-2 protein expression after treatment
with BcI-2oligonucleotides
Cells (1 x 106) were treated for 96 h with Bcl-2 antisenses oligo-
nucleotides (2jM) or sense oligonucleotides (control). Lysate from
both the detached and the adherent cells was subjected to SDS-
PAGE, as previously described (Zhang et al, 1995). Briefly, cell
extracts were boiled in sample buffer for 5 min and loaded onto
12.5% SDS-polyacrylamide gel. After electrophoresis at 150V,
proteins were transferred to Immobilon-P membrane (Millipore,
Bedford, MA, USA), blocked with Tris-buffered saline containing
Tween 20 (0.1%) and gelatin (1%) at pH 7.5 for 1 h, then incubated
with antibodies to Bcl-2 (Santa Cruz Biotechnology, Santa Cruz,
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CA, USA). Proteins were detected using an enhanced chemilumi-
nescence (ECL) system (Amersham Life Sciences, Bucks, UK).
Lysate from NB-4 leukaemic cells was used as a positive control to
confirm the migration ofthe BCL-2 band. To ensure even loading of
proteins, the membrane was stripped and reprobed with an antibody
to the cell surface adhesion molecule E-cadherin (Transduction
Laboratories, Lexington, KY, USA). Densitometry was performed
on the bands to quantify the changes in detected protein.
Statistical analysis
The effect of the combination of antisense Bcl-2 oligonucleotide
and 2-HPR was assessed by comparing the means of either agent
acting alone with their combined action using the Student's t-test.
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RESULTS
Cell proliferation assays
The dose-response curve for inhibition ofcell growth after 4 days,
shown in Figure 1, revealed that the optimum concentration for
differential activity between S and AS oligonucleotide was 2,M.
Cell growth with AS oligonucleotide was 62% (± 4%) of control,
whereas treatment with the S oligonucleotide was 95% (± 4.5%) of
non-treated control. Multiple-dosing (every 24 h) did not further
inhibit growth by the S oligonucleotide and only minimally
increased growth inhibition (5%) by the AS oligonucleotide (data
not shown).
We also investigated whether growth inhibition was additively
enhanced by the combination of the optimum AS oligonucleotide
concentration (2 ,UM) with various retinoids (ATRA, 9cRA and 2-
HPR). Dose-response curves revealed that each compound had
modest activity alone (data not shown). We used a dose for further
experiments that had a noticeable but submaximal inhibitory
effect; this effect was obtained by all three retinoids at 0.1 ,IM and
was equal to approximately 30% growth inhibition. The growth
inhibition values for all three compounds (ATRA, 9cRA and 2-
HPR) at 0.1 JIM were 24 ± 3.9% (± s.e.), 32 ± 4.8% and 30 ± 0.6%
respectively. When combined, only 2-HPR with Bcl-2 antisense
oligonucleotide resulted in significantly reduced cell growth
compared with either AS Bcl-2 or 2-HPR acting alone (66 ± 0.8%
and 70 ± 0.6%, respectively, compared with 43 ± 2.6%, P < 0.05)
(Figure 2 and data not shown). The S oligonucleotides plus 2-HPR
combination was no more inhibitory than 2-HPR alone (data not
shown).
Expression of Bcl-2 protein
Western blot analysis was used to confirm that AS oligonucleo-
tides down-regulated expression of the Bcl-2 protein. DU-145
cells were cultured for 96 h with 2 JIM of sense (control) or anti-
sense Bcl-2 oligonucleotides, and cell lysates were resolved by
Western blot. We normalized total protein levels by probing with
antibody to constitutively expressed E-cadherin. Treatment with
AS oligonucleotide resulted in 46% reduction in the expression of
Bcl-2 compared with sense-treated control (data not shown).
Detection of apoptosis
Cells exposed to the antisense or sense control oligonucleotides
were examined for the apoptosis induction by both orientation of
Figure 2 Single-dose effects of sense and antisense Bcl-2 oligonucleotides
in combination with 2-HPR on DU-145 cell number in liquid culture. Cells
were exposed for 4 days after which time they were counted. Results are
expressed as the mean per cent (± s.e.m.) of control with no oligonucleotide.
Each point represents a mean of at least three experiments with duplicate
dishes
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Figure 3 Effects of sense and antisense Bcl-2oligonucleotides on
apoptosis. DU-145 prostate cancer cells were exposed to either sense or
antisense Bcl-2oligonucleotides alone (2 gM) or antisense Bcl-2
oligonucleotides in combination with 2-HPR (0.1 gM) for 18, 36 and 96 h.
Apoptosis was measured by (A) expression of phosphatidylserine on the cell
surface or DNA fragmentation (B) as described in Materials and methods.
Cells were treated with etoposide (50 gg ml-') as a positive control
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membrane phospholipids and end-labelling ofDNA strand breaks.
Loss of the anisotropic orientation of the cellular membrane as
revealed by expression of negatively charged phosphatidylserine
on the cell surface as a marker ofthe initial stages of apoptosis. As
this is a relatively early event during apoptosis, we used this
method after 18 and 36 h of exposure to AS and S oligo-
nucleotides. Figure 3A shows that 2 gM Bcl-2 antisense oligo-
nucleotides, either alone or in combination with 2-HPR, did not
induce a significant apoptotic response at either 18 or 36 h,
although etoposide resulted in cells positive for Annexin V [6%
(± 0.6%) and 12% (± 1.5%) for 18 and 36 h respectively].
The fragmentation of nucleosomal DNA is another hallmark of
apoptosis. We used a TUNEL assay to detect DNA fragmentation.
After a 96-h exposure to 2 gM antisense Bcl-2 oligonucleotides,
either alone or in combination with 2 HPR, we were unable to
detect any significant apoptosis, although almost 40% (± 7%) of
the control cells treated with etoposide were tagged by BrdU-
FITC-conjugated antibodies (Figure 3B).
DISCUSSION
Previous studies have demonstrated a clear role for up-regulation
of Bcl-2 expression in various cancer cells, including hormonally
independent prostate cancer, as a mechanism of extending cell
viability and inhibiting the normal regulation of apoptosis
(McConkey et al, 1996). In the present study, we have examined
the effects ofBcl-2 AS oligonucleotides on DU-145, a hormonally
insensitive prostate cancer cell line, and demonstrated a significant
level of both growth inhibition in liquid culture after 4 days and,
using the same culture condition, we demonstrated decreased
expression of Bcl-2 protein. The growth inhibition was signifi-
cantly enhanced in the presence of the synthetic retinoid 2-HPR.
We had anticipated that the principal mechanism of inhibition
would be increased apoptosis; however, in both the short- and
medium-term assays, we were unable to demonstrate any increase
in apoptosis with the AS Bcl-2 oligonucleotide, even in the
presence of 2-HPR.
Apoptosis has been demonstrated in many normal types of
tissues as a regulatory mechanism for controlling the number of
terminally differentiated cells, for example during haematopoiesis
(Sachs and Lotem, 1993). In the normal prostate gland, androgen
control of apoptosis is thought to be critical in regulating cell
number (Wright et al, 1996). Prostate cancer usually retains this
sensitivity and androgen blockade can lead to apoptotic cell death
in approximately 85% ofcases, although the majority will reverse
this sensitivity within 3 years. The LNCaP prostate cancer cell line
expresses androgen receptors, and androgens can up-regulate Bcl-
2, thereby inhibiting apoptosis (Bercham et al, 1995); neverthe-
less, the removal of androgens from the cells does not by itself
result in apoptosis.
The role of Bcl-2 in apoptosis is complex and has been
extensively reviewed (Yang and Korsmeyer, 1996). The apoptosis
pathway involves an array of heterodimeric proteins that interact
and undergo post-transcriptional modifications (Golstein, 1997) to
form a cell survival/death rheostat, with their ratios and phos-
phorylation states determining the cell fate. In the DU-145 cell
line, the androgen receptor is not expressed and the cells do not
undergo apoptosis in androgen-depleted conditions, as is found in
patients whose prostate cancer is no longer responsive to androgen
withdrawal. The inability to trigger an apoptotic response in
liquid culture, reported in the current study, would suggest that the
apoptotic pathway is compromised in these cells, and this may
represent one aspect of an increasingly transformed phenotype;
DU-145 cells have aberrant expression of androgen receptor, p53,
Rb and the pl6ink4A tumour-suppressor gene (Carrol et al, 1993;
Gaddipati et al, 1994; Isaacs et al, 1994; Tamimi et al, 1996).
Furthermore, an analysis of clinical prostate cancer samples
undertaken by Apakama et al (1996) has shown that samples that
had over-expression of both Bcl-2 and p53 were synergistically
more likely to be hormonally resistant, and therefore apoptosis-
resistant, than samples that displayed aberrant expression of only
one of these key regulatory proteins.
Thus, although we demonstrated decreased expression of Bcl-2
in response to AS Bcl-2 oligonucleotide, this was not sufficient to
turn the cell rheostat towards apoptosis, even in the presence of an
inhibitory retinoid. This finding may reflect the complexity of the
apoptotic pathway in which other proteins inhibit apoptosis, such
as BCL-xL (Yang and Korsmeyer, 1996) or BAGI (Takayama et
al, 1995), or the result of aberrant function of apoptosis promoting
proteins such as p53. Indeed, recently, one such protein, BAX, has
been shown to be mutated in DU-145 (Rampino et al, 1997). An in
vivo murine model of the normal prostate revealed that, although
down-regulation of Bcl-2 was an initial apoptotic step, the actual
trigger for apoptosis was mediated through the Fas receptor. Thus,
the cellular machinery to initiate a full apoptotic response is multi-
step (Suzuki et al, 1994).
Although apoptosis was not detected under our experimental
conditions, significant growth inhibition was observed in the pres-
ence of the Bcl-2 AS oligonucleotide and was significantly
enhanced by the synthetic retinoid 2-HPR. In DU-145 cells, Bcl-2
may not solely function as a regulator of apoptosis, but may
mediate another pathway ofgrowth inhibition. For example, Bcl-2
is localized to the mitochondria, endoplasmic reticulum and
nuclear envelope and appears to have a complex interaction with
various aspects of the cell machinery. Thus, down-regulation of
Bcl-2 protein may be associated with limiting energy production,
because in the current study cell viability did not decrease (data
not shown) whereas cell number did.
Other studies have examined the effects of AS Bcl-2 oligonu-
cleotide treatment on various cell types. For example, previous
studies have demonstrated inhibited cell growth without apoptosis
in lymphoma cell lines (Smith et al, 1995); however, others,
including studies with fresh acute myeloid leukaemia samples,
have demonstrated decreased cell growth as a result of apoptosis
(Campos et al, 1994; Keith et al, 1995). Therefore, the effects of
antisense Bcl-2 oligonucleotides on apoptosis appearto be specific
to the tissue or the type ofcancer.
Our study showed that the inhibitory effects of AS Bcl-2
oligonucleotides were enhanced by 2-HPR, but not ATRA or
9cRA. Although ATRA and other retinoids have been intensively
investigated in various cancers, they have not shown significant
potency against DU-145 and other similar androgen-insensitive
prostate cancer cell lines or primary tissue samples. Ofnote, N-(4-
hydroxyphenyl)all-trans retinamide, which is isomeric to 2-HPR,
has been reported to induce apoptosis in a prostate cancer cell line
(JCAI) after their long-term exposure (>6 days) at high dose
(Hsieh et al, 1995b). Its mechanism differs from that of ATRA
(Delia et al, 1995; Ponzoni et al, 1995; Kazmi et al, 1996; Wang
and Phang, 1996), requiring RNA transcription and protein
synthesis, and its regulation is mediated by protein kinase C. The
exact mechanism ofaction of4-HPR, or the related compound (2-
HPR) used in the current study, remains largely unknown; as does
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the question of why 2-HPR demonstrates additive effects with the
AS Bcl-2. Nevertheless, the existing clinical information about
both of these compounds possibly makes such a combination an
attractive therapeutic option for advanced hormone-refractory
prostate cancer. It is also notable because DU-145 is particularly
resistant to most retinoids, requiring high doses to achieve modest
inhibition; however, significant inhibition was achieved in the
current study with a relatively low dose ofretinoid in combination
with Bcl-2 antisense oligonucleotide.
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